Group 1 - The core viewpoint is that the innovative drug sector is expected to remain the most important investment theme in the pharmaceutical sector for the upcoming year, with significant positive catalysts emerging [2] - The Hong Kong pharmaceutical ETF (159718.SZ) has seen a 0.74% increase, with notable gains in constituent stocks such as Kangfang Biopharma (4.57%), MicroPort Scientific (4.15%), and Zai Lab (3.95%) [1] - The U.S. job market showed a significant decline in November, with private sector jobs decreasing by 32,000, the largest drop in two and a half years, which has heightened expectations for a Federal Reserve interest rate cut [1] Group 2 - The pharmaceutical sector has experienced a 2-3 month adjustment period, leading to a relative low in stock prices, market expectations, and institutional allocations, thus enhancing investment safety margins [2] - Multiple favorable policies are set to be released, including December's medical insurance negotiations and international conferences, which are expected to positively impact the industry [2] - The U.S. biotechnology index (XBI) has risen by 2.84%, reflecting a strong performance in the healthcare sector, with expectations of a gradual recovery in global innovative drug financing and demand [1][2]

Group 1 - The Hong Kong pharmaceutical ETF (159718) increased by 1.34% on November 26, with a trading volume of 44.50 million yuan [1] - The ETF's shares decreased by 3 million, bringing the total to 241 million shares, with an increase of 3 million shares over the last 20 trading days [1] - The latest net asset value of the ETF is 237 million yuan [1] Group 2 - The performance benchmark for the Hong Kong pharmaceutical ETF is the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (adjusted for exchange rates) [1] - The fund is managed by Ping An Fund Management Co., Ltd., with the fund manager being Weng Xin [1] - Since its establishment on December 16, 2021, the ETF has returned -1.43%, while the return over the past month is 0.78% [1]

Core Viewpoint - The Hong Kong pharmaceutical ETF (159718) experienced a decline of 2.65% on October 30, with a trading volume of 47.8497 million yuan [1] Group 1: Fund Performance - The ETF's total shares increased by 1 million, bringing the total to 239 million shares [1] - The latest net asset value is calculated at 229 million yuan [1] - Since its inception on December 16, 2021, the fund has returned -4.18%, with a one-month return of -12.27% [1] Group 2: Management and Benchmark - The ETF is managed by Ping An Fund Management Co., Ltd., with the fund manager being Weng Xin [1] - The performance benchmark for the ETF is the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (adjusted for exchange rates) [1]

Core Viewpoint - The Hong Kong pharmaceutical ETF (159718) experienced a decline of 2.82% on October 17, with a trading volume of 50.7552 million yuan, indicating a downward trend in the market [1] Group 1: ETF Performance - The ETF's shares decreased by 1 million, bringing the total to 223 million shares, with a reduction of 20 million shares over the last 20 trading days [1] - The latest net asset value is calculated at 220 million yuan [1] - Since its establishment on December 16, 2021, the ETF has returned -1.24%, with a one-month return of -9.39% [1] Group 2: Management and Benchmark - The ETF's performance benchmark is the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (adjusted for exchange rates) [1] - The fund is managed by Ping An Fund Management Co., Ltd., with the fund manager being Weng Xin [1]

Core Insights - The Hong Kong pharmaceutical ETF (159718) increased by 4.09% on September 5, with a trading volume of 105 million yuan [1] - The ETF's shares decreased by 4 million, bringing the total to 235 million shares, with a reduction of 26 million shares over the last 20 trading days [1] - The latest net asset value of the ETF is 262 million yuan [1] - The ETF's performance benchmark is the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (adjusted for exchange rates) [1] - Managed by Ping An Fund Management Co., Ltd., the ETF has achieved a return of 11.70% since its inception on December 16, 2021, and a return of 7.66% over the past month [1]